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AN INEVITABLE CONFLICT: THE SUBORDINATION OF 
CONTRACT PRINCIPLES TO INFORMED CONSENT IN 
THE BUSINESS OF BANKING UMBILICAL CORD 
BLOOD 
ABSTRACT 
This Note explores the business of banking umbilical cord blood for 
later, and potentially life-saving, use. It discusses the importance of the 
stem cells found in umbilical cord blood, and the complexities involved in 
applying business models to its collection, storage, and use. Furthermore, 
this Note discusses how contracts governing the storage and use of umbil-
ical cord blood can conflict with concepts of human dignity and informed 
consent. It concludes that in the event umbilical cord blood banking con-
tracts conflict with informed consent, the contract should be subordinated 
to a person’s understanding, acquired through procedures intended to 
achieve the patient, or parent’s, informed consent. 
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INTRODUCTION 
In this age of reproductive and medical innovation, there is a growing 
tension between the application of legal principles and business models to 
the sale, storage, collection, and use of bodily fluids and parts and our 
society’s inalienable concepts of human dignity and bodily integrity. Now, 
there is a thriving and lucrative market for products and services that only 
a few decades ago were considered too sacrosanct to place a monetary 
value on. As that attitude has passed, the difficulty is how to create and 
mold our legal framework to monitor and govern areas that are so emo-
tionally charged and tied to previously ungoverned values. 
The storage and use of umbilical cord cells is one of these markets—
few of which have advanced as rapidly or as recently.1 Since the discovery 
of hematopoietic stem cells in umbilical cord blood in the late 1980s and 
early 1990s, umbilical cord blood has become a precious source of poten-
tially life-saving biological material.2 Umbilical cord blood, which until 
this time had been discarded as medical waste, can now be frozen, stored, 
and preserved in case the cells are needed in the future. The cells can be 
used by the baby whose umbilical cord they are extracted from, or by a 
family member who is a bone-marrow match, with several advantages 
over traditional bone marrow transplantation.3 But in part because of the 
                                                                                                                         
1 Similar markets such as sperm donation, in-vitro fertilization, or embryo donation 
have not seen the level of interest or medical advancement as has the market for umbili-
cal cord cells. See ETHICS COMM. OF THE AM. SOC’Y FOR REPROD. MED., AMERICAN 
SOCIETY FOR REPRODUCTIVE MEDICINE: DEFINING EMBRYO DONATION (2009), http://ww 
w.sart.org/uploadedFiles/ASRM_Content/News_and_Publications/Ethics_Committee_Re
ports_and_Statements/DefiningEmbryoDonation.pdf; Emily Shenk, Sperm-Donor Chil-
dren Face Challenges in Learning Their Medical History, WASH. POST (Sept. 26, 2011), 
http://www.washingtonpost.com/national/health-science/sperm-donor-children-face-chall 
enges-in-learning-their-medical-history/2011/07/01/gIQAX9hwzK_story.html; History of 
IVF, HUMAN FERTILISATION & EMBRYOLOGY AUTHORITY, http://www.hfea.gov.uk/histor 
y-of-ivf.html (last visited Feb. 24, 2014). 
2 Hematopoietic Stem Cells, Stem Cell Information, NAT’L INST. OF HEALTH, http://ste 
mcells.nih.gov/info/scireport/chapter5.asp (last visited Feb. 24, 2014) [hereinafter HSCs]. 
3 See generally Sheila R. Kirschenbaum, Banking on Discord: Property Conflicts in 
the Transplantation of Umbilical Cord Stem Cells, 39 ARIZ. L. REV. 1391 (1997). Ad-
vantages of cord blood transplantation over bone marrow transplantation include de-
creased racial and ethnic donor limitation, timeliness of transplantation, greater tolerance 
of HLA mismatch, and decreased severity of graft-versus-host disease. Susan P. Raine, 
Informed Consent in Umbilical Cord Blood Collection, Storage, and Donation: A Bloody 
Mess, HEALTH LAW & POL’Y INST., HEALTH LAW PERSPECTIVES, Apr. 4, 2007, at 1, http: 
//www.law.uh.edu/healthlaw/perspectives/2007/%28SR%29CordBlood.pdf (citing Ken-
neth Moise, Jr., M.D., Umbilical Cord Stem Cells, 106 OBSTETRICS & GYNECOLOGY 
1393, 1394 (2005)). 
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rapid and recent proliferation of the potential uses of umbilical cord cells, 
the issues arising from their storage and use remain unsettled. Umbilical 
cord cells, like other stem cells, have the potential to cure fatal illness, pre-
vent genetic conditions from developing, and solve medical mysteries—
offering treatment for about seventy different kinds of conditions and dis-
eases.4 But myriad legal, social, and moral complications are attached to the 
storage, preservation, and prospective use of these cells; the outcome, if not 
proactively attended to, threatens the violation of not only property rights or 
contractual agreements but also the violation of  human dignity. 
The business of umbilical cell storage, use, and donation is a compli-
cated and messy intersection of contract rights and informed consent. 
When concepts of informed consent cannot fill the gaps that arise, it is 
logical and reasonable to fill the gaps with contract doctrine. In situations 
where a contradiction arises between informed consent and an umbilical-
cord-cell storage contract, however, concepts of informed consent should 
take precedence over terms delineated in the contract. 
Part I of this Note will address the importance and use of stem cells in 
order to understand umbilical cord blood cells; specifically, it will exam-
ine how the two are similar and also how they differ. Part II will explain 
umbilical cord blood cells, what they are, and what they are used for, as 
well as the promises they hold for medical advancement. Part III will 
explore the storage system, how it operates, and how it is accessed. 
The final portion of this Note will address the problems arising from 
umbilical cord blood cell storage and use. Because both contract and in-
formed consent doctrines govern the storage and use of these cells, there 
are times when they conflict; this Note argues that in those situations in-
formed consent should take precedence over contractual terms. Lastly, the 
Note will use the parallel example of fertilized embryo storage to support 
the contention that informed consent should trump contract terms when 
the two conflict. 
I. BACKGROUND 
In 1951, an impoverished African American cervical cancer patient 
unknowingly donated a sample of human tissue that changed the world.5 
                                                                                                                         
4 Erica Lloyd, Umbilical Cord Blood: The Future of Stem Cell Research?, NAT’L 
GEOGRAPHIC NEWS (Apr. 6, 2006), http://news.nationalgeographic.com/news/2006/04/04 
06_060406_cord_blood.html. 
5 Robert Truog, Aaron Kesselheim & Steven Joffe, Paying Patients for Their Tissue: 
The Legacy of Henrietta Lacks, SCI. MAG., July 2012, at 37, 38; see also REBECCA 
SKLOOT, THE IMMORTAL LIFE OF HENRIETTA LACKS (2010). 
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The tissue obtained by her physicians at Johns Hopkins University con-
tained cancer cells that were so aggressive that when placed in the perfect 
environment, they became immortal—that is, capable of unlimited cell 
replication.6 Her physicians did not obtain her consent before using her 
tissue for research, nor did they receive any personal financial gain from 
the cell line; they did, however, enable cell research never before possi-
ble.7 From this specific cell line—now referred to as the HeLa line—
researchers were able to develop the polio vaccine, determine what would 
happen to human cells in zero gravity, and explore cloning, gene mapping, 
in vitro fertilization, and discover stem cells.8 
The discovery of the HeLa cell line spurred an age of organ and body 
tissue sale, donation, and adoption; from this age came increased ease and 
proficiency of experimentation.9 With the increase in availability of sam-
ples, it logically follows that more experiments can occur for less cost 
resulting in more gain.10 
A. The Importance of Stem Cells 
Fast forward almost thirty years from when the HeLa cell was first 
replicated to the discovery of the stem cell.11 A stem cell is a cell that 
“self-renews but also can give rise to several differentiated cell types, such 
as muscle cells, heart cells or brain cells.”12 In order to identify a cell as a 
stem cell, scientists must prove that “one single isolated cell can give rise 
to all the specialized cells it is supposed to produce ....”13 At the same 
                                                                                                                         
6 See Truog, supra note 5, at 37, 38. 
7 Id. 
8 Sarah Zielinski, Henrietta Lacks’ ‘Immortal Cells,’ SMITHSONIAN.COM (Jan. 22, 
2010), http://www.smithsonianmag.com/science-nature/Henrietta-Lacks-Immortal-Cells.ht 
ml#ixzz2BBk8iosz. 
9 Id. 
10 Truog, supra note 5, at 38. In August of 2013, a settlement was reached with the 
family of Henrietta Lacks regarding the HeLa strain. Although they will not be financial-
ly compensated for the cells, they will now have some control over scientists’ access to 
the cells’ DNA code. The settlement was struck after the Lacks Family voiced concerns 
about the privacy issues surrounding the publicity of the genetic makeup of HeLa cells. 
See Malcolm Ritter, Henrietta Lacks’ Family, Feds Reach Settlement On Use of DNA 
Info, HUFFINGTON POST (Aug. 7, 2013, 3:59 PM), http://www.huffingtonpost.com/2013/0 
8/07/henrietta-lacks-family-settlement-on-dna-info_n_3720936.html. 
11 Ian Murnaghan, History of Stem Cells, EXPLORE STEM CELLS (Oct. 16, 2013), http:// 
www.exploreste mcells.co.uk/historystemcellresearch.html.  
12 Suzanne Kadereit & Pamela J. Hines, An Overview of Stem Cell Research, 39 NEW 
ENG. L. REV. 607, 607 (2004–05). 
13 Id. at 608. 
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time, that cell must also produce cells that give rise to the stem cell pheno-
type.14 Until recently, scientists mostly dealt with two kinds of stem cells: 
embryonic stem cells and non-embryonic “somatic” or “adult” stem 
cells.15 In 1998 scientists found a way to derive stem cells from human 
embryos and then grow the cells in a laboratory to research them.16 In 
2006, researchers made another breakthrough by identifying the possibil-
ity of genetically “reprogramming” specialized adult cells to assume a 
“stem cell-like state.”17 They named this new type of stem cell induced 
pluripotent stem cells.18 
In the first few days of the development of an embryo, the inner cells 
(embryonic stem cells) give rise to the cells which eventually make up the 
entire body, including all of the many specialized cells that make up the 
heart, lungs, skin, sperm, eggs, and all other organs and tissues.19 In some 
adult tissues, such as bone marrow, adult stem cells regenerate cells to 
replace those that have been lost.20 Because stem cells are able to regener-
ate with ease and into any number of different kinds of cells stem cells 
offer new possibilities in the treatment and cure of diseases such as diabe-
tes and heart disease. However, “much work remains to be done in the 
laboratory and the clinic to understand how to use these cells for cell-
based therapies to treat disease.”21 
Umbilical cord blood cells are found in blood from the umbilical cord 
and placenta after childbirth.22 The type of stem cells found in bone mar-
row and blood are called hematopoietic stem cells (HSC).23 The extraction 
and use of the different kinds of stem cells is a very complicated science 
involving many forms of comprehensive testing. However, the basic idea 
is that there are two types of HSC: long-term cells, which are capable of 
self-renewal, and short-term cells, which can immediately regenerate dif-
ferent kinds of stem cells but cannot normally renew themselves over the 
                                                                                                                         
14 Id. 
15 Stem Cell Basics, Stem Cell Information, NAT’L INST. OF HEALTH, http://stemcells.n 
ih.gov/info/basics/basics1.asp (last visited Feb. 24, 2014). 
16 Id. 
17 Id. 
18 Id. 
19 Id. 
20 Id. 
21 Id.; see also Timothy Caulfield, Stem Cell Research and Economic Promises, 38 
J.L. MED. & ETHICS 303 (2010). 
22 Umbilical Cord Blood, MARCH OF DIMES, http://www.marchofdimes.com/pregnanc 
y/labor_umbilical.html (last visited Feb. 24, 2014). 
23 Raine, supra note 3, at 1. 
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long term.24 Both of these mechanisms are integral in the restorative quali-
ties HSCs possess.25 Before physicians discovered HSCs in the blood of 
umbilical cords and placentas, the only way to obtain these cells was 
through the drawing and transfer of bone marrow.26 That process is ex-
tremely painful for the donor and comes with the risks associated with a 
general anesthetic.27 As a result, there was a shortage of donations.28 The 
effect of the discovery of HSCs in umbilical cord blood and placentas 
significantly increased the availability of HSCs for donation and has made 
13,000 donations available for transplantation in the largest U.S. public 
umbilical cord blood bank.29 Currently, scientists are still researching 
umbilical cord blood to compare it against bone marrow stem cells.30 
Some have suggested that umbilical cord blood is qualitatively superior to 
bone marrow stem cells, but no scientific evidence has been published to 
support this claim.31 
B. The Uses and Benefits of Umbilical Cord Blood Cells 
Hematopoietic stem cells have been found to treat various genetic dis-
orders that affect the blood and immune system, leukemia and other can-
cers, and some inherited disorders of body chemistry.32 With the use of stem 
cell transplantation patients suffering from cancers of the blood, such as 
leukemia, lymphoma, or myeloma; hemoglobinopathies, such as beta-
thalassemia, sickle cell anaemia, or Fanconi’s anaemia; and immunodefi-
ciencies, such as severe combined immune deficiency and Wiskott Aldrich 
Syndrome, can essentially reconstitute their immune systems after chemo-
therapy and radiotherapy.33 The patient’s bone marrow is reloaded with the 
HSCs from the donor, and the replenishment enables the patient to begin to 
produce healthy blood cells independently again.34 Other than the diseases 
and conditions umbilical cord blood cells have already been found to treat, 
research continues to assess their ability to treat degenerative diseases, such 
                                                                                                                         
24 HSCs, supra note 2. 
25 Id. 
26 Id.  
27 Id. See also Kirschenbaum, supra note 3, at 1397. 
28 See Kirschenbaum, supra note 3, at 1392, 1399 n.63, 1415. 
29 See HSCs, supra note 2. 
30 See id. 
31 See id. 
32 See id. 
33 Madelaine Saginur, Linda Kharaboyan & Bartha Maria Knoppers, Umbilical Cord 
Blood Stem Cells: Issues with Private and Public Banks, 12 HEALTH L.J. 17, 18 (2004). 
34 Id. 
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as Parkinson’s, Alzheimer’s, Lou Gehrig’s, and Multiple Sclerosis;35 post-
traumatic disorders, such as post-stroke and spinal cord injuries;36 and heredi-
tary diseases of the central nervous system such as Huntington’s disease.37 
Another benefit of umbilical cord blood cells is the relatively immedi-
ate availability of a sample once a match is found, due partly to a large 
donor pool. With umbilical cord blood cells, the necessary testing to find a 
match is done before the blood is preserved and stored; once a match is 
found, it can then be retrieved more readily and easily than a bone marrow 
donor match.38 Furthermore, umbilical cord blood cells are less “picky” 
when it comes to matching donors with recipients.39 The proteins in blood 
cells that determine whether a donor is a match for a recipient are heredi-
tary, which is why before the mass banking of umbilical cord blood cells, 
the best way a patient found a match was to look within his family or 
racial group.40 Narrowing the chances of a successful match even more, 
bone marrow transplants require a close to perfect match.41 But with um-
bilical cord blood cells, the “immaturity [of the cells] permits more liberal 
[protein] matching, and ... collection [and transplantation] can be per-
formed on a larger and more systematic scale.”42 
C. The Storage and Donation of Umbilical Cord Blood Cells 
For all of the aforementioned reasons, there has been an increased impe-
tus to encourage donation and storage of umbilical cord blood cells over the 
last two decades.43 The process of collecting cord blood from the placenta is 
relatively simple and has become routine for physicians involved in the 
delivery of babies.44 The process begins with the expectant parents choosing 
                                                                                                                         
35 Id. (citing R.A. Nash et al., High-Dose Immunosuppressive Therapy and Autolo-
gous Peripheral Blood Stem Cell Transplantation for Severe Multiple Sclerosis, 102 
BLOOD 2364 (2003)). 
36 Id. (citing D.A. Peterson, Umbilical Cord Blood Cells and Brain Stroke Injury: 
Bringing in Fresh Blood to Address an Old Problem, 114 J. OF CLINICAL INVESTIGATION 
312 (2004); Z.M. Zhao et al., Intraspinal Transplantation of CD34+ Human Umbilical 
Cord Blood Cells After Spinal Cord Hemisection Injury Improves Functional Recovery in 
Adult Rats, 13 CELL TRANSPLANTATION 113 (2004)). 
37 Id. (citing N. Ende & R. Chen, Human Umbilical Cord Blood Cells Ameliorate 
Huntington’s Disease in Transgenic Mice, 32 J. MED. 231 (2001)). 
38 Id. 
39 Id. 
40 Id. 
41 Id. 
42 Id. 
43 HSCs, supra note 2. 
44 Courtney Witte, Cord Blood Storage Property and Liability Issues, 26 J. LEGAL 
MED. 275, 276 (2005). 
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a bank to store the baby’s cord blood.45 The bank sends the collection kit, 
which the parents bring with them to the delivery room.46 An instructional 
video is shown to the collecting physician, and the blood is drawn from the 
placenta either while still in utero or within ten minutes of delivery.47 After 
the blood is drawn, the necessary tests are done on the sample to ensure 
viability and safety, and the cord blood is combined with an anticoagulant 
and a “cryopreservative” and then stored under liquid nitrogen.48 The cord 
blood must be received by the bank within twenty-two hours.49 
Expectant parents have the choice of banking the umbilical cord blood 
cells with private or public banks. With public banks, donation is free but 
their availability is limited.50 Before donating to a public bank, parents 
will likely have to undergo comprehensive physical and mental health 
questionnaires and testing.51 The public banks then store the cells until a 
matching recipient is in need of them, at which time the cells from the 
unrelated, stored donor are used to hopefully save the recipient’s life.52 
Alternatively, a private market has developed to capitalize on the life-
saving potential of preserving these cells. Companies have created a sys-
tem that allows parents to “bank” their child’s blood in case the child ever 
needs a treatment or transplant in the future.53 With these banks, a baby’s 
own cells will be available as insurance, thus increasing the likelihood of a 
successful treatment.54 These stored cells could also be used, if found to be 
a match, by a sibling or other family member in need of HSCs.55 
States largely determine the system of public storage, although there is a 
national marrow donor program registry, which provides a complete listing of 
participating hospitals.56 Many states provide information regarding storage 
banks through the state’s department of health or equivalent agency.57 
                                                                                                                         
45 Jodi Fredrickson, Umbilical Cord Blood Stem Cells: My Body Makes Them, But Do I 
Get To Keep Them? Analysis of the FDA Proposed Regulations and the Impact on Individual 
Constitutional Property Rights, 14 J. CONTEMP. HEALTH L. & POL’Y 477, 486 (1997–98). 
46 Id. 
47 Id. at 486; see also Umbilical Cord Blood, supra note 22.  
48 See Frederickson, supra note 45, at 487. 
49 Id. 
50 See Saginur et al., supra note 33, at 22. 
51 Id. at 28. 
52 Kirschenbaum, supra note 3, at 1392. 
53 Id. 
54 Id. 
55 Id. 
56 Saginur et al., supra note 33, at 22 nn.44–45. 
57 See, e.g., Pennsylvania Umbilical Cord Blood Banking and Donation, PA. DEP’T OF 
HEALTH, http://www.portal.state.pa.us/portal/server.pt/community/infant___newborn’s_he 
alth/14173/umbilical_cord_blood_banking_home/557783 (last visited Feb. 24, 2014); 
Donating Umbilical Cord Blood, R.I. BLOOD CENTER, http://www.ribc.org/full/inner/cor 
dblood.shtml (last visited Feb. 24, 2014); Cord Blood: The New Jersey Cord Blood Bank 
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Private banks provide contracts and documents that govern their ar-
rangements with parents. Each company sets its own terms, but on average, 
the cost of collecting and storing cord blood, cord tissue, and placenta tissue 
for twenty years is about $6000, or alternatively about $600 per month for 
twelve months.58 The contracts governing the terms of the transaction are 
constructed by the company and delineate numerous requirements that each 
prospective parent is expected to read, understand, and consent to.59 
II. THE PROBLEMS ARISING FROM THE BANKING OF UMBILICAL CORD 
BLOOD CELLS 
There are at least four thorny issues that are outside the scope of this 
Note that have arisen out of the proliferation of the banking of umbilical 
cord blood cells. One of the most controversial is the debate surrounding 
private versus public banking of umbilical cord stem cells.60 This debate is 
concerned with the appropriate amount of regulation of private banks and 
the risks of abuse and misuse as a result of an inadequate regulatory 
framework. The debate is also concerned with protecting the rights and 
interests of the parents involved in the transaction. Some researchers believe 
public banks solve the problems presented by private banks by making the 
cells available to all and eliminating the possibility for solicitation and ex-
ploitation of the vulnerable position many parents are in while making the 
decision to use a bank to store bodily fluids and parts.61 Entangled in the 
conversation about private banking is the assertion that it is socioeconomi-
cally unjust. Some critics argue that if these cells provide life-saving 
treatment, the government should foot the bill to store them and make the 
option available to all irrespective of means.62 
                                                                                                                         
(NJCBB), COMMUNITY BLOOD SERVICES, http://www.communitybloodservices.org/cb_nj 
cbb.php (last visited Feb. 24, 2014). 
58 Cord Blood & Cord Tissue & Placenta Tissue Banking Costs, AMERICORD 
REGISTRY, https://cordadvantage.com/cord-blood-costs-and-services.html (last visited 
Feb. 24, 2014); Cord Blood Banking Costs with Cord Tissue, FAMILYCORD, https://ww 
w.familycord.com/enroll-online (last visited Feb. 24, 2014); Pricing Cord Blood, Cord 
Tissue Stem Cells, CRYO-CELL INT’L, http://www.cryo-cell.com/cord-blood/banking-pric 
es/new-clients (last visited Feb. 24, 2014). 
59 Saginur et al., supra note 33, at 23. 
60 Id. at 22–34; see also Shannon Folger, The Neglect of the Umbilical Cord: Ohio’s 
Failure to Adequately Promote Banking of Umbilical Cord Blood Stem Cells and the 
Need for New Legislation, 22 J. L. & HEALTH 137, 155–65 (2008). 
61 Saginur et al., supra note 33, at 22. 
62 Id. at 24. 
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Another issue stemming from the increased use of umbilical cord blood 
cells involves the status of umbilical cord blood for purposes of the Federal 
Drug Administration (FDA).63 The FDA has been in the process of solidify-
ing a regulatory framework for this new technology that relies upon the 
classification of the cells as technology or medicine or biologics.64 Howev-
er, it is difficult to establish a regulatory framework for a material that, in 
some jurisdictions, is still considered “medical waste.”65 Eventually, the 
FDA settled on an official definition of umbilical cord blood and deter-
mined that cord blood stored for potential future use by a patient “unrelated 
to the donor meets the definition of ‘drug’ under the Food, Drug & Cosmet-
ic Act and ‘biological product’ under section 351 of the Public Health Ser-
vice Act.”66 The FDA also requires that cord blood stored publically, in 
other words  to be donated, must meet additional requirements and “be 
licensed under a biologics license application … or subject to an investiga-
tional new drug application … before use.”67 Cord blood stored for personal 
use or for use by close relatives, however, does not require approval before 
use.68 Private cord banks must comply with other FDA requirements, in-
cluding “establishment registration and listing, donor screening and testing 
for infectious diseases (except when used for the original donor), reporting 
and labeling requirements, and compliance with current good tissue practice 
regulations.”69 There are also concerns that while the FDA is ironing out the 
details to approve certain stem cell treatments, patients seeking life-saving 
treatment will be “vulnerable to unscrupulous providers of stem cell treat-
ments that are illegal and potentially harmful.”70 
Lastly, the property rights associated with these materials have been 
unclear since the beginning of the storage of umbilical cord blood. Since 
the FDA now recognizes umbilical cords and their blood and cells as more 
than medical waste, questions have been raised regarding whether cord 
blood is property and as such may be the subject of ownership, possession, 
use, and enjoyment.71 Because the umbilical cord by nature is the link 
                                                                                                                         
63 See, e.g., id. at 28–29; see also Frederickson, supra note 45, at 477. 
64 See Frederickson, supra note 45, at 479. 
65 Saginur et al., supra note 33, at 24. 
66 Cord Blood Banking—Information for Consumers, Vaccines, Blood & Biologics, 
U.S. FOOD & DRUG ADMIN. (July 23, 2012), http://www.fda.gov/biologicsbloodvaccines 
/resourcesforyou/consumers/ucm236044.htm. 
67 Id. 
68 Id. 
69 Id. 
70 FDA Warns About Stem Cell Claims, U.S. FOOD & DRUG ADMIN. (July 5, 2012), 
http://www.fda.gov/forconsumers/consumerupdates/ucm286155.htm. 
71 Witte, supra note 44, at 279. 
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between the mother and the baby, many parties involved in the research, 
storage, and use of it, question to whom it belongs.72 
The last few decades have enjoyed immeasurable advancements in re-
productive and medical technologies. With these advancements, especially 
with biological materials used for assistance in reproduction, have come 
debates surrounding the property rights contained in body tissue. Over the 
years, this debate—typically framed in terms of Moore v. Regents of the 
University of California and its progeny—has defined the terms that gov-
ern property rights in body tissue.73 The progression has moved toward 
recognizing that people have limited property rights in their human tissues 
after removal from their body.74 The parties claiming property rights in 
their tissue were given some sort of decision-making authority because 
their tissue was a unique type of property in that they were capable of 
contributing to the conception of a human.75 Umbilical cord blood cells, 
however, hold their value differently: their property value is defined by the 
life that could be saved.76 
It is well established that the sale of organs is illegal.77 The sale of bodi-
ly fluids, such as plasma and sperm, however, is permitted, and done fre-
quently.78 But this different treatment can be explained by distinguishing 
umbilical cord blood from “body parts.”79 The term “body parts” includes 
all “organs, tissues, fluids, cells, and genetic material on the contours of or 
within the human body, or removed from it, except for waste products.”80 
Included in the category of body parts, therefore, are lymph and bone 
marrow, as well as complete organs, such as kidneys.81 But body parts 
such as marrow and kidneys require invasive and sometimes extremely 
painful surgery for both removal and insertion, whereas the gathering of 
cord blood does not include any action besides the preservation of the 
umbilical cord.82 Umbilical cord blood also differs from whole blood 
                                                                                                                         
72 Id. 
73 793 P.2d 479 (Cal. 1990); Hecht v. Superior Court, 20 Cal. Rptr. 2d 275 (Ct. App. 
1993); Davis v. Davis, 842 S.W.2d 588 (Tenn. 1992). 
74 Kirschenbaum, supra note 3, at 1407. 
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found in children and adults in that it is not replenishable and contains 
fewer stem cells, proportionally, than whole blood.83 
This Note is not concerned with the exact classification of property 
rights attributed to umbilical cord blood cells. However, drawing analo-
gies to similar fluids and the treatment of them will help to clarify further 
discussion and satisfy some of the ambiguity inherent in this subject. 
A. The Background of Informed Consent 
Informed consent is one of the foundational principles of the medical 
profession. Dating back to the Nuremberg Code, it has become a basic 
requirement of medical research that all participants in an experiment must 
give intentional consent free of “undue inuence such as ‘coercion, fraud, 
duress, or deceit.’”84 While the Nuremberg Code was an important ad-
vancement for the rights of subjects, it failed to provide any framework for 
how this consent would be administered, monitored and confirmed.85 In 
1964 the Declaration of Helsinki addressed some of the shortcomings of 
the Nuremberg Code.86 Developed by the World Medical Association as a 
set of ethical principles to govern medical research, the Declaration of 
Helsinki addressed informed consent.87 
The Declaration requires that all research subjects voluntarily and 
knowingly participate in the research project. In particular, it requires that 
subjects be informed that:  
 subjects must be volunteers and informed participants in 
the research project;  
 subjects have the right to safeguard their integrity, privacy 
and confidentiality;  
 potential subjects must be adequately informed of the aims, 
methods, sources of funding, any possible conflicts of in-
terest, and institutional affiliations of the researcher;  
 potential subjects must also be informed of the anticipated 
benefits and potential risks of the study and the discomfort 
it may entail;  
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 subjects must be informed of the right to abstain from par-
ticipation in the study or to withdraw consent to participate 
at any time without reprisal; and  
 subjects must be informed that, when obtaining informed 
consent, the physician should be particularly cautious in the 
event that a dependent relationship exists between the sub-
ject and the physician or if the subject may otherwise con-
sent under duress.88 
Shortly thereafter Congress established a commission that created the 
Belmont Report, a set of principles to be followed in all research.89 One of 
the principles, which they called respect for persons, directly involves the 
process of obtaining consent from research participants.90 As described in 
the report, this principle establishes that “all human participants are to ‘be 
treated as autonomous agents capable of self-determination.’”91 Implied in 
this principle is the requirement that all participants must be given sufficient 
information about what they are participating in, which they also must un-
derstand, and they must have the right to withdraw their participation and 
data at any point.92 Although more regulations have grown from these initial 
sets of guidelines, the basic tenants remain intact and provide the concepts 
underlying the importance of informed consent in the biomedical field. 
Regulations mandate that banks obtain some form of consent—either 
actual or implied—from a patient unless he is incompetent to consent or a 
minor.93 In circumstances where the patient cannot consent for himself, a 
parent, legal guardian, or next of kin must consent to the treatment or 
action in question.94 Absent any reliable source to speak on behalf of the 
patient, a court can produce a court order.95 Consent is not required in 
emergency situations, such as when the parent, legal guardian, or next of 
kin cannot be found and delay would threaten life or safety.96 
In order to be valid, consent must be informed, meaning that the con-
senting person must have ample knowledge, information, and understand-
ing to be able to make an intelligent and complete decision.97 A physician 
has knowledge above and beyond what a patient, who is not also the same 
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type of doctor, could reasonably be expected to have about the details and 
intricacies of medicine. Because of this disparity, and the fact that the 
relationship between a doctor and a patient is fiduciary as well as contrac-
tual, the burden is on the physician to convey all information necessary to 
make an informed decision to the patient.98 In the absence of adequate 
information, many courts find that consent is actually not truly consent at 
all, but “merely a submission to an intended procedure.”99 In the event that 
a physician withholds information, provides information which is mislead-
ing or false, or performs a procedure other than that which the patient was 
informed of and consented to, such as removing the left leg instead of the 
right one, the physician may be liable for the tort of medical malpractice 
or battery, and punitive damages may be awarded.100 
B. Informed Consent in Research and Biobanking 
Informed consent matters to umbilical-cord-blood-cell storage for at 
least four reasons. First, the customers or donors must consent to the terms 
of their storage or donation agreements, and need to fully understand what 
those terms mean. Such terms include issues of privacy and identity.101 
Second, it is vital that parents understand the research that might be done 
using the stored or leftover cord blood as part of their informed consent, but 
potential research purposes are not always clear at the time an agreement is 
made.102 Third, informed consent requires a participant have the right to 
withdraw, and this right raises business-related issues when it comes to 
this type of storage and banking.103 Finally, there are myriad issues regarding 
custodianship and ownership with these kinds of arrangements that informed 
consent cannot always prevent.104 
Recent developments in genome analysis and biobanking have made in-
formed consent regarding privacy and protection of participants’ identities a 
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cause for concern.105 Advancements have made it so that scientists can 
identify a donor, and his susceptibilities to many diseases, simply from 
genome analysis of stored tissue.106 It may soon become possible for re-
searchers to “identify a person in a public database from other information 
collected during a study, such as data on ethnic background, location and 
medical factors unique to the study participants, or to predict a person’s 
appearance from his or her DNA.”107 
The use and potential for reuse of large collections of biomedical data 
have made truly informed consent of research nearly impossible.108 Some 
ethicists argue that because the people giving consent cannot always fore-
see all the possible outcomes of a study, they therefore cannot be expected 
to truly know what they are consenting to, making informed consent unob-
tainable.109 This concern has become especially salient in genome research 
seeking to reuse samples for purposes other than those that were originally 
intended.110 To enable researchers to do this, researchers are beginning to 
ask patients to give broad consent in order to cover many, or even all, po-
tential future research endeavors using their samples.111 Although this con-
cept of broad consent is a way to circumvent informed-consent issues, some 
patient advocates argue that broad consent fails to meet the tenets of in-
formed consent provided by the Declaration of Helsinki.112 As the Declara-
tion describes, part of informed consent means that the subject must be 
adequately informed of the “aims, methods, sources of funding, any possi-
ble conflicts of interest, institutional affiliations of the researcher, the 
anticipated benefits and potential risks of the study and the discomfort it 
may entail and any other relevant aspects of the study.”113 
It is difficult to imagine how a potential subject could be adequately 
informed at the time of recruitment about any future research that may 
involve their sample, particularly when new research techniques and re-
search questions raise ethical concerns that “could not have been foreseen 
at the time the initial consent was given.”114 Some researchers believe 
obtaining permission to use samples for any possible research is permissible 
                                                                                                                         
105 Hayden, supra note 102, at 312. 
106 Id. 
107 Id. at 313.  
108 E.A. Whitley, N. Kanellopoulou & J. Kaye, Consent and Research Governance in 
Biobanks: Evidence From Focus Groups With Medical Researchers, 15 PUBLIC HEALTH 
GENOMICS 232, 233 (2012).  
109 Hayden, supra note 102, at 312. 
110 Whitley et al., supra note 108. 
111 Id. 
112 Id.  
113 See WORLD HEALTH ORGANIZATION, supra note 86, at 374. 
114 Whitley et al., supra note 108, at 233. 
2014] BANKING UMBILICAL CORD BLOOD 637 
since that is “the whole point of a generic tissue bank.”115 However, current 
ethical guidelines do not allow broad consent to cover “any possible re-
search” and often require amendment to informed consent if the sample is 
to be subjected to DNA-related research.116 
A participant’s right of withdrawal or revocation plays a critical role in 
fulfillment of informed consent and the design of medical research. This 
right, which has been recognized both internationally and domestically, 
does not require a participant to present a rationale for their decision to 
withdraw.117 The ability to withdraw both consent and participation is a 
core method of respecting and protecting dignity and autonomy.118 Over 
the past several years, there has been an impetus within the field of 
healthcare to allow patients to have a greater say in their clinical care and 
what happens to their information.119 
There are scientific as well as business risks involved in allowing patients 
to revoke their consent. Without the security of participation, researchers may 
be less likely to start projects in the first place. Participants’ withdrawal 
could ruin the effectiveness of or perhaps even invalidate a study. This 
withdrawal would, of course, have scientific implications, but the financial 
burden of an unsuccessful clinical trial or study is also severe.120 
Lastly, the custodianship and ownership issues—despite a company’s 
best efforts to address them—will always be difficult when tissue belonging 
to both a mother and a child is involved. It is difficult to discern who does 
or should have ownership rights to a body part that two humans share, let 
alone the added complication if a father were to claim partial ownership for 
his part in creating the baby. When multiple interests are involved and the 
future is so unpredictable, informed consent is the best chance at protecting 
the rights and interests of all the parties involved. However, some issues are 
outside the scope of what informed consent can solve. 
C. Public Banking Terms 
Public banking is largely run and regulated on a state-by-state basis, 
although many participating hospitals are members of the National Mar-
row Donor Program, a network of banks.121 A survey of states consisting 
of Texas, Arizona, New Jersey, New York, and Missouri, the states with 
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the most readily accessible information, can serve as an indication of the 
general trends. 
 Although the terms of the donation and storage arrange-
ment are not easily accessible online, the New Jersey Cord 
Blood Bank lists whole umbilical cords, including blood, as 
research materials available to them.122 General access to 
this product presumably means that cord and blood cells 
could potentially be subjected to research that donors may 
never be made aware of.  
 New York provides an online consent form that informs 
the potential donor that their donated sample may be sub-
jected to research in order to find new treatment options 
and to learn how to improve the clinical results of cord 
blood transplantation.123  
 Arizona does not mention research, but does promise that the 
identity of the baby and mother are always kept confidential 
by the public cord blood bank.124 The cord blood unit is giv-
en a number at the hospital, and this is how it is identified on 
the registry and at the public cord blood bank.125  
 Texas, however, operates completely differently. The pro-
gram covering southern Texas archives publically donated 
cord blood units collected at hospitals partnered with the 
Texas Cord Blood Bank at no cost to the donor.126 The pro-
gram stores cord blood samples for families with a first de-
gree relative (that is, full biological sibling or birth parent) 
of the baby in question that is a candidate for a cord blood 
transplant.127 This first degree relative of the baby must be di-
agnosed with a disease or disorder approved by the program, 
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but once diagnosed, the cord blood will be stored exclusively 
for this family at no cost.128  
 Missouri’s consent form, available through its website, 
states that a sample may not be “suitable for transplanta-
tion—for instance, if the volume of the cord blood collect-
ed is too small or it has too few of the cells required for 
transplantation—but might still be usable for research into 
stem cell biology or other health-related research.”129 But 
Missouri further explains that it would require the persons 
conducting the research to get approval from the local Insti-
tutional Review Board to insure that the research is meeting 
federal guidelines.130 
D. Informed Consent Found in Private Storage Terms of Agreement 
There are myriad private and public banks throughout the United 
States, and the world, that store umbilical cord blood for clients who hope 
to never need it.131 Many of these banks can be located with ease on the 
internet, and information about the specifics of the process is typically 
available. Hospitals and doctors have also started providing patients with 
the information necessary to understand to storing or donating umbilical 
cord blood cells. This practice, informing potential donors well before 
delivery, has gained traction as the debate surrounding the storage of um-
bilical cord blood has progressed.132 This Note looks at two popular pri-
vate banks, which are representative of the industry. 
1. Americord 
Americord is a national private cord bank that operates under its own 
contractual terms established by the contract it distributes to secure pay-
ment.133 The agreement spells out the rights of the adult-donors and the 
child from whom the stem cells come. The contract provides that the stem 
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cells belong to the child, and when the child reaches the age of legal ma-
jority in his or her jurisdiction, the child has the right to decide if, or how, 
the stem cells will be used or continue to be stored.134 The contract re-
quires that when the child reaches the age of legal majority in his jurisdic-
tion, the clients must notify the child that his cord blood was collected at 
birth, and the stem cells from the sample are being stored by Americord.135 
The contract stipulates that if the clients have already told the child these 
facts as a minor, the clients must remind the child when he reaches the age 
of majority.136 
When the child reaches majority, he can then decide whether to enter 
into a separate agreement with Americord, endorse the current agreement, 
or terminate the agreement altogether.137 If the child, upon reaching major-
ity, decides to terminate the agreement the adult-donors are notified and 
lose control of the sample.138 The adult-donors are responsible, however, 
for any fees associated with transferring the sample to a different blood 
bank if the child chooses to transfer the sample.139 If the child upon reach-
ing majority does not contact Americord, Americord will deem the child 
to have endorsed the agreement. In that case, the adult-donors are treated 
like the child’s agents. 140 The document goes on to address termination, 
and in all capital letters and bold font exclaims that in the event of termina-
tion, if the clients or child do not request otherwise, the sample shall belong 
to Americord to do with as they see fit.141 
2. Cryo-Cell 
Cryo-Cell was the world’s first private cord blood bank to separate and 
store stem cells starting in 1992.142 Its contract recognizes that the parent 
is executing the agreement in the client’s capacity as the child’s legal 
guardian.143 It delineates that absent termination of the contract, Cryo-Cell 
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has no rights to the stem cells.144 In the event that the client wishes to 
assign his rights and obligations under the contract to another party, the 
new party must sign a new agreement to confirm its understanding of the 
terms and conditions of Cryo-Cell’s service.145 If a client whose account is 
current wishes to discontinue the service, the client may inform Cryo-Cell 
Customer Service, and all ownership rights to the stem cells will transfer 
to Cryo-Cell.146 
After the child reaches majority, the client may continue to pay storage 
fees for the benefit of child, absent contrary written instruction by the child 
himself. The contract with Cryo-Cell provides that it may be cancelled by a 
client’s written request at any time.147 Because the contract states that it 
will honor the parents request for cancellation after the child reaches ma-
jority, the terms seem to imply that the consent of the child is not required 
for a client to cancel the contract.148  
When the child has reached the age of majority, the child will then 
have ownership claims to the sample; however, since Cryo-Cell does not 
have a contractual relationship with the child, Cryo-Cell will rely on the 
client’s representation that the client is acting on behalf of the child and 
will honor any request for cancellation that is made after the child reaches 
the age of majority.149 
3. Ambiguities and Conflicts 
Upon examination of the private banking agreements, it is not difficult 
to imagine situations that could arise that would put children’s or clients’ 
interests in conflict with the terms of the contract. The two most obvious 
ambiguities can be found in the rights of the guardians of the child’s sam-
ple and the rights of the storage bank upon default of the client. Both of 
these situations present areas of tension, in which banks must place the 
terms of the contract before standards of informed consent and patient 
rights, especially if the samples are used in a way the child or client are 
not made aware of beforehand. 
The most salient issue not resolved by the contract arises when the 
rights of guardians to use the sample to save the life of a sibling or close 
family member comes into question. The agreement acknowledges the 
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ownership rights of the sample as belonging to the child. However, there is 
no guidance on what the client has the right to do until the child reaches 
the age of majority. These problems present a conundrum for banks. Fur-
thermore, these problems illuminate the areas in which the children whose 
tissue is being stored may be exploited or the rights overlooked. Who is 
advocating for them? 
III. THE CLASH BETWEEN INFORMED CONSENT AND CONTRACT TERMS 
After identifying the gaps, the question becomes what is to be done 
about them. In a market as new as this, which does not present the same 
widespread social or political appeal as more hot-button political areas 
such as embryo and sperm storage and donation, there is no motivation to 
ensure proper regulation and treatment of the parties involved. However, 
proper regulation of the storage of the umbilical cord blood cells can pro-
tect the businesses as well. 
A. Concepts of Informed Consent Should Take Precedence Over Contrac-
tual Terms 
There is not yet case law discussing the conflicts of interests that can 
arise from ambiguous storage agreements. Drawing a parallel to treatment 
of the storage and distribution of embryos provides the closest analogy. 
The two situations are strikingly different in that the storage of embryos 
necessarily involves the potential for the creation of life. This potential 
raises the stakes, as the right to procreate—or not—is much more compli-
cated than the storage of umbilical cord blood cells. 
However, there are also similarities between the two kinds of storage 
systems that make the comparison relevant. Both involve the storage and 
use of potentially important tissue that partially belongs to two separate 
parties: in the case of embryos, the participating potential parents and in 
the case of the umbilical cord blood, the mother and the child. 
The courts have consistently respected standards and concepts of in-
formed consent over the terms of a contract, and exercised their authority to 
apply balancing tests to weigh the interests of the parties rather than stick to 
the confines of the agreement. In Reber v. Reiss, the court relied solely upon 
the informed consent document to govern the details of the divorce ar-
rangement, and the details of the contract were not referenced.150 The Su-
preme Court of Iowa held that it would violate public policy to enforce a 
prior agreement regarding use or disposition of embryos when a party has 
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changed his or her mind.151 Time and again courts, on the grounds of public 
policy, have declined to enforce contracts that violated protected constitu-
tional rights.152 In Schloendorff v. Society of New York Hospital, Justice 
Cardozo recognized that “[e]very human being of adult years and sound 
mind has a right to determine what shall be done with his own body,” the 
right to our body is one worthy of protection, even from the first moments 
of life.153 Therefore, when these conflicts arise, as they inevitably will, the 
course of action that should be followed is one governed by principles of 
informed consent and not the terms delineated in the contract. 
B. How This Inevitable Conflict Will Affect Businesses 
It is estimated that “[m]ore than 780,000 cord blood units are stored in 
over 130 private cord blood banks, worldwide, and over 400,000 units in 
more than 100 quality controlled public cord blood banks.”154 The global 
stem-cell market is anticipated to rise to a staggering 60 billion dollars by 
2015.155 Given the size and scope of the market, and the fact that it is 
continuing to grow, the aforementioned policy would likely have an im-
pact on the business of banking umbilical cord blood cells. The inability to 
rely exclusively on the terms provided in their contracts would open pri-
vate banks to increased liability and decreased certainty in their dealings 
with clients. 
However, there are ways to mitigate the impact this could have on a 
business. Ensuring informed consent is rarely contrary to good-faith busi-
ness interests, and often protects businesses from the possibility of costly 
lawsuits from clients, who never truly understood the terms of the agree-
ment. Clients who are informed are more likely to remain happy clients, 
which for marketing purposes is good for business. 
Understanding that one of the basic tenants of informed consent is the 
right to withdraw, a negative effect of failing to implement this policy is 
that clients could potentially insist upon the withdrawal of, or refuse to 
allow, any samples to be experimented on after default of their contract. 
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Such a withdrawal could spur a domino effect of complications for com-
panies who sell the leftover samples to research labs or to non-related 
clients for use. Therefore, in the interest of protecting themselves from 
liability down the line, operating with the understanding that principles of 
informed consent will override contractual terms will enable companies to 
better predict potential areas of conflict and better serve the interests of the 
client while doing so. 
It is worth noting that the future of umbilical cord blood storage is far 
from certain. According to the American Medical Association, the proba-
bility of an individual actually using the stem cells retrieved during cord 
blood banking later in life is about 1 in 20,000.156 Furthermore, the typical 
cord blood harvest is only sufficient for a recipient weighing less than 115 
pounds.157 Balancing these factors and the burdensome expense of bank-
ing for long periods of time, some families may decide that storing the 
cells is no longer an option or not one that is worthwhile to pursue.158 The 
future of umbilical cord blood storage hangs in the balance of this calcu-
lus, and if more parents decide not to take the precaution the industry 
could potentially die out as quickly as it has risen. 
CONCLUSION 
In 2004, an author by the name of Jodi Picoult wrote a book called My 
Sister’s Keeper, which six years later was made into a movie and gained 
national attention for the heart-wrenching storyline and well-known 
cast.159 The book centers around a family, and in particular a little girl, 
who was the product of pre-implantation genetic diagnosis, and was con-
ceived as a bone marrow match for her ill sister.160 The book follows her 
struggle and the struggle of her family to respect her autonomy while 
enlisting her help to save the life of her sister, and raises questions that 
cause any mother, sister, father, or friend to grapple with.161 Among them, 
questions such as whether parents can force a reluctant child to become an 
organ donor for a fatally ill sibling; and even if not legally barred, should 
they?162 The drama and heartbreak of the storyline adds a humane element 
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160 Id. 
161 Id. 
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to an otherwise hypothetical question, but the foundation mirrors that of 
the storage and potential for use of umbilical cord blood cells. Regardless 
of age, intent, or money paid, the answers to questions about who should 
be able to make decisions regarding issues of bodily integrity and treat-
ment are far from clear. 
In an age of personalized medicine, where we can control human traits 
and genes and use the birth of one to the advantage of another, conflicts 
between individual autonomy and dignity are becoming more prevalent. 
The response to My Sister’s Keeper showcases the troubled reactions from 
people pondering these questions. From a business perspective, the emo-
tional and moral elements make it all the more important to protect the 
interests of the clients as well as the interests of the business, and the most 
prudent way to do this is to abide by a policy of informed consent doctrine. 
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